Comparative effectiveness of 177 Lu-PSMA-617 versus 177 Lu-PSMA-I&T for metastatic castration-resistant prostate cancer (EANM 2026) - Sep 29, 2026 - Abstract #EP-0920; "In this real-world cohort, ¹⁷⁷Lu-PSMA-617 and ¹⁷⁷Lu-PSMA-I&T demonstrated comparable biochemical response; however, ¹⁷⁷Lu-PSMA-617 was associated with a significantly longer overall survival, suggesting a potential survival advantage. These findings add to growing evidence that ligand-specific differences may influence clinical outcomes and support further prospective comparative studies."
HEOR • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
R. Fakkert; K. J. Nijenhuis; T. F. F. T. Ververs; C. P. Bruijnen; A. J. A. T. Braat; B. de Keizer; M. G. E. H. Lam
|